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Title: Gabapentinoids for treatment of neuropathic pain: a medicines usage 
evaluation at the Groote Schuur hospital chronic pain management clinic 
  
Background 
Neuropathic pain (NP), defined as pain caused by a lesion or disease of the 
somatosensory system, affects 6.9 – 10 % of people worldwide. Pregabalin is 
currently recommended as a first line drug for NP in South Africa. 
 
Methods 
A cross-sectional retrospective descriptive medicines usage evaluation (MUE) of 
Pregabalin at Groote Schuur Chronic Pain clinic for the year 2017 was conducted. A 
MUE using a standardized data collection form was performed on 100 randomly 
selected folders. Data are summarized using descriptive statistics.  
 
Results 
The majority of cases were women (76) with a mean age of 55.9y (SD12.49). A 
diagnosis of NP was recorded in 58 folders and a “possible” diagnosis recorded in 7 
folders. In 79 cases there was no mention of a tool/method used to diagnose NP. The 
most common condition diagnosed was chronic post-surgical pain with a neuropathic 
component (n=16), followed by NP (n=15). The most common initiating and current 
dose of Pregabalin was 75mg twice daily. In 56 patients, Pregabalin was prescribed in 
conjunction with a tricyclic antidepressant (TCA) or selective noradrenaline reuptake 




Based on this MUE we recommend the use of screening tools for the diagnosis of 
neuropathic pain, and a focus on the initiating dose of Pregabalin.  The use of a 
standardized assessment document and the interdisciplinary team input at this clinic 
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Section A: Introduction 
 
Neuropathic pain is defined as pain caused by a lesion or disease of the 
somatosensory system. Neuropathic pain is not a single disease, but a syndrome, 
which may be caused by a range of different diseases and lesions in the 
somatosensory nervous system, manifesting as an array of symptoms and signs.
1
 
Neuropathic pain can further be classified on the basis of etiology; thus, lesions can 
be central or peripheral, focal or generalized. There are multiple screening tools to aid 
in the diagnosis of neuropathic pain, including the Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS), Douleur Neuropathique 4 (DN4), Pain detect, ID 
Pain, and the neuropathic pain questionnaire.
2, 3
 A recent systematic review reported 
an estimated population prevalence of pain with neuropathic characteristics of 
between 6.9% and 10%.
4, 5
 
For South Africa, no published studies of the prevalence of neuropathic pain could be 
found. However, it is possible that there is a higher prevalence than elsewhere due to 
the burden of HIV/AIDS and diabetes, both of which are often associated with painful 
peripheral neuropathies.
6
 The prevalence of neuropathic pain was reported as 23% 
among South African AIDS patients who had not received prior antiretroviral 




The pathology of neuropathic pain is complex and it is therefore not surprising that all 
treatment guidelines recommend multimodal treatment strategies and a 
biopsychosocial approach.
8
 To select the most effective multimodal approach, the 
pathological mechanisms that contribute to neuropathic pain need to be considered to 
inform the selection of treatments that target those mechanisms.  
The consequences of lesions in the somatosensory system include peripheral and 
central sensitization.
9
 Lesions in the peripheral nerves result in peripheral 
sensitization via an increased expression of Na
+
 channels and voltage gated Ca
2+
 
channels in the C- and Aδ-nociceptive fibres.
9
 This sensitization results in 
spontaneous ectopic-like discharges, decreased threshold of activation, and enhanced 
responsiveness to stimuli. Input from sensitized C-fibres can initiate and maintain 
activity dependant central sensitization in the dorsal horn of the spinal cord with 
enhanced neural excitability due to enhanced neurotransmitter release (glutamate) and 
 9 
upregulation of glutamate (N-Methyl D-Aspartate) NMDA receptors.
10
 The enhanced 
excitability and upregulation results in expansion of the receptive field and abnormal 
neural sprouting within the dorsal horn of the spinal cord.
9,10
 All these changes alter 
nociceptive transmission manifesting clinically as hyperalgesia and allodynia.  
Another mechanism that contributes to central sensitization is the dysfunction of the 
descending inhibitory serotonergic and noradrenergic pathways.
10
 Originating from 
the anterior cingulate gyrus, amygdala and hypothalamus, and traveling via the brain 
stem nuclei in the periaqueductal grey and rostroventral medial medulla, the 
descending inhibitory pathways modulate the spinal transmission of nociceptive input 
at the spinal cord.
10
 The neurotransmitters involved include noradrenaline, serotonin, 
and endogenous opioids. After a nerve injury, these pathways begin to dysfunction 
resulting in the effect of noradrenaline on α2 noradrenergic receptors being suspended, 
with a net effect of the serotonergic input changing from inhibition to facilitation.
11
 
Therefore, the use of tricyclic antidepressants and serotonin noradrenaline reuptake 
inhibitors (SNRI) in the treatment of NP aims to facilitate endogenous inhibition and 
inhibit central sensitization. 
As is evident from the above discussion of neuropathic mechanisms, the Ca
2+ 




 is required for exocytosis of vesicles containing neurotransmitters from the 
presynaptic neuron into the synapse. By blocking or decreasing activity of the Ca
2+ 
channels, a reduction in the synaptic release of excitatory neurotransmitters such as 
glutamate, substance P, noradrenaline, serotonin and calcitonin gene-related peptide 
results. By reducing the release of excitatory neurotransmitters, the effect of 
peripheral sensitization can be reduced, and central sensitization mechanisms 
diminished. The gabapentinoids, derivatives of the inhibitory neurotransmitter g-
aminobutyric acid (GABA), bind to the α2δ auxiliary subunit of voltage-gated calcium 
channels, decreasing the influx of Ca
2+
 into the presynaptic neuron.
12
 
The gabapentinoids include Pregabalin and gabapentin. Pregabalin is more potent and 
has a higher binding affinity for the α2δ subunit of voltage gated calcium channels 
than gabapentin 
12
. In South Africa, Pregabalini s currently recommended as a first 
line drug for treatment of neuropathic pain. 
13-15
  
Pregabalin has been used at the Groote Schuur Hospital (GSH)Chronic Pain Clinic for 
eight years. The license on the drug has recently expired, and, with a potential shift in 
 10 
availability, it is appropriate to conduct a Medicines Usage Evaluation (MUE) to 
optimize future practice. The GSH Chronic Pain Clinic is a specialist run clinic, 
treating an average of 100 patients monthly. At GSH, in line with WC DoH 
guidelines, Pregabalin and gabapentin must be consultant initiated i.e. prescriptions 
cannot be filled without the approval of a consultant aneasthetist listed as working in 
the Chronic Pain Clinic. On average, patients seen at the clinic are 52.8 y; 
predominantly female (68.7%) and unemployed (51%). We conducted a MUE of 
Pregabalin in the chronic pain management clinic (CPMC) of Groote Schuur Hospital 
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The prevalence of chronic musculoskeletal pain in South Africa has been reported to 
be higher than that in developed countries by multiple authors.[1, 2] A Western Cape 
community clinic based study reported the prevalence of chronic musculoskeletal pain 
to be 36%, higher than the 24% reported in the USA. [2] Chronic musculoskeletal 
pain is costly to manage due to its recurrence and potentially debilitating nature. 
When the chronic pain has a neuropathic component, management may increase in 
complexity.[3] 
 
Neuropathic pain is defined as pain which occurs due to a lesion or disease affecting 
the sensory nervous system. [4] In South Africa, it is estimated that up to 30% of 
people with diabetes suffer from neuropathic pain[5], similarly up to 30% of people 
living with HIV develop painful peripheral neuropathy. [6] The prevalence of chronic 
pain musculoskeletal pain with a neuropathic component in South Africa is unknown, 
however it is estimated that up to 50% of people with chronic lower back pain will 
have a neuropathic component. [3]Other chronic pain conditions which present with a 
neuropathic component include: post-traumatic neuralgia (peripheral neuropathic); 
phantom limb pain (central neuropathic); stroke and other brain injuries (central 
neuropathic); and complex regional pain syndrome (Type I: central neuropathic; Type 
II: peripheral neuropathic). [3] 
 
Chronic pain has an impact on multiple spheres of an individual’s life such as 
psychological state, mood and activities of daily living.[7] When there is a 
neuropathic component, the impact on mood, function and participation is increased. 
[8] 
 
The South African guidelines for the management of neuropathic pain recommend 
that if neuropathic pain is suspected, clinicians should screen for it using an 
appropriate tool such as the DN4[9] or the LANSS [10]. There appears to be 
consensus that on confirmation that the pain has a neuropathic component, treatment 
should be initiated with pregabalin or gabapentin as a first line drug with tricyclic 
antidepressants and topical lidocaine suggested as first line alternatives. [11-14] 
Pregabalin and gabapentin are α2δ-ligands with similar targets but with differing 
16 
pharmacokinetics. Gabapentin, the older of the two drugs, has nonlinear 
pharmacokinetics and dosing requires careful titration. Pregabalin has linear 
pharmacokinetics and can thus be titrated more rapidly to effective dosages. [13]  
The drawback of Pregabalin as a first-line treatment for neuropathic pain in South 
Africa is that it is a relatively new drug, still under license to its developers with cost 
implications for the user. At Groote Schuur Hospital, the prescribing of pregabalin is 
restricted to specialist neurologist, neurosurgeon, oncologist, chronic pain clinic 
practitioner and rehabilitation centers. The license on the drug has recently expired 
which means that generic forms of the drug may shortly become available. It is 
possible that this will result in greater availability and consequent changes in 
prescribing practices. 
Guidelines recommend interdisciplinary treatment strategies which integrate 
pharmacological and non-pharmacological treatments rather than one-dimensional 
pharmacological management alone. [3, 15]  This means that prescribing of the drug 
should take place in conjunction with non-pharmacological treatments. Chronic pain 
management is complex and expensive. The direct and indirect costs (i.e. cost 
associated with consequent disability, lost time from work, reduced productivity) of 
medical care are substantial. The most effective treatment strategies target a variety of 
factors simultaneously, using the biopsychosocial multidisciplinary approach. In 
2014, the International Association for the Study of Pain (IASP) released guidelines 
that defined a multidisciplinary pain center as being a facility staffed by a variety of 
health care professionals with expertise in pain management, including physicians, 
nurses, mental health professionals, and physical therapists. Chronic pain requires a 
biopsychosocial approach using pharmacological and non-pharmacological 
approaches in tandem. 
Given that pregabalin has been used at the GSH Chronic Pain Clinic for 5 years 
(personal communication, Dr van Nugteren) and that the license on the drug has 
recently expired with a potential shift in availability, it is appropriate to conduct a 
MUE to determine to who and how pregabalin has been used in the clinic to inform 
training and practice in the future. 
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2.AIMS and OBJECTIVES 
 
The aim of this study is to conduct a Medicines Use Evaluation (MUE) for pregabalin 
in the chronic pain management clinic (CPMC) of Groote Schuur Hospital. 
 
Using a cross-sectional chart review design, in patients who have been prescribed 
pregabalin at the CPMC , the objectives are to: 
1. Describe the medical conditions for which pregabalin is being prescribed 
using the WHO ICD codes 
2. Describe the prescribing practices of clinicians including: 
a. Full description of pain including type, severity and duration 
b. Patient details including age, gender, pregnancy, breastfeeding, 
allergies, comorbidities and whether they are receiving a disability 
grant 
c. Consideration of other medications and interaction with pregabalin 
d. Pregabalin dose, interval and duration documentation 
e. Follow up plan mentioned: including assessment of response to 
treatment or referral for non-pharmacological treatment  






3.1:RESEARCH DESIGN  
A cross sectional descriptive study will be conducted. This type of study design will 
allow for the study of the characteristics of a population at one point in time, help in 
identifying the common medical conditions that pregabalin is being prescribed for and 
describe the prescribing practices of clinicians.  
 
3.2:SAMPLE SIZE 
To obtain a representative sample of prescribing practices in this population, the 
WHO recommends sampling a population of 100 patients. [16] As this study aims to 
describe prescribing practice of clinicians in Groote Schuur chronic pain clinic, the 
sample has been calculated based on a total number of patients seen in the chronic 
pain clinic on a monthly base.  
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3.3:PROCEDURE 
Following ethical approval from the Faculty of Health Sciences Human Research 
Ethics Committee and the Groote Schuur Hospital Department of Health (DoH) 
Ethics Committee,  
 
3.4:MEASUREMENT INSTRUMENTS 
A data collection sheet based on the literature has been developed (Appendix A). 
Each question in the data collection sheet has been peer reviewed and referenced with 
supporting literature to ensure validity. The excel data collection tool will be 
populated with dropdown menus to reduce variability in responses. 
 
3.5:DATA ANALYSIS 
Data from the MUE will be entered into an excel spreadsheet. Descriptive statistics 
will be used to summarize the data. Further analysis of prescribing practice will be 
conducted using Chi-squared analysis of frequency distributions to explore 




Ethical approval will be applied from the University of Cape Town Faculty of Health 
Sciences Human Research Ethics Committee and the Groote Schuur Hospital Ethics 
committee. Approval for the chart review process will also be obtained from senior 
consultant responsible for the CPMC and pharmacy manager. 
 
The principles of the Declaration of Helsinki will be adhered to throughout. [17] The 
principles of autonomy, beneficence, non-maleficence and justice will be applied. 
[18] Autonomy will be maintained by keeping all patient details anonymous.  As this 
is a chart review, patients will not be approached directly. Data collection will be 
conducted using two laptops. Information will be combined and saved to an external 
hard drive daily. The information gathered on the personal laptops will then be 
deleted to ensure that no information is available.  The data will be stored on a 
password protected external hard drive kept in a locked office in the Department of 
Anaesthesia and Perioperative Medicine. 
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Beneficence will be observed by reviewing the patient’s prescription charts 
individually, allowing the researchers to identify pharmacological errors that might 
cause patient harm.  This study will also benefit patients’ chronic pain management 
by addressing the role and importance of referral to multidisciplinary teams. 
Identifying and addressing the incorrect prescribing practice of clinicians and thus 
improving clinician’s pregabalin prescribing practice in the future will ensure non-
maleficence. In terms of justice this study will help in saving the DoH money by 





Copies of MUE: 100 copies.  R1.50 per copy. Estimated cost R150. 
6.PROJECT TIMELINES 
 
Data collection: June – July 2018 
 
Data analysis: July - August 2018 
 
Write up: August -September 2018 
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Background: Neuropathic pain (NP), defined as pain caused by a lesion or disease of 
the somatosensory system, affects 6.9 – 10 % of people worldwide. Pregabalin is 
currently recommended as a first line drug for NP in South Africa. 
Methods: A cross-sectional, retrospective, descriptive medicines usage evaluation 
(MUE) of Pregabalin at Groote Schuur Hospital (GSH) Chronic Pain Management 
clinic for the year 2017 was conducted. A MUE using a standardized data collection 
form was performed on 100 randomly selected patient folders. Data was summarized 
using descriptive statistics.  
Results: The majority of cases were women (76) with a mean age of 55.9y (SD12.49). 
A diagnosis of NP was recorded in 58 folders and a “possible” diagnosis recorded in 7 
folders. In 79 cases there was no mention of a tool/method used to diagnose NP. The 
most common condition diagnosed was chronic post-surgical pain with a neuropathic 
component (n=16), followed by NP (n=15). The most common initiating and current 
dose of Pregabalin was 75mg twice daily. In 56 patients, Pregabalin was prescribed in 
conjunction with a tricyclic antidepressant (TCA) or selective noradrenaline reuptake 
inhibitor (SNRI). Patient education was documented as having taken place in 76 of 
cases. 
Conclusions: Based on this MUE we recommend the use of screening tools for the 
diagnosis of neuropathic pain, and a focus on the initiating dose of Pregabalin.  The 
use of a standardized assessment document and the interdisciplinary team input at this 





Neuropathic pain is defined as pain caused by a lesion or disease of the 
somatosensory system.
1
 Neuropathic pain is not a single disease, but a syndrome, 
which may be caused by a range of different diseases and lesions, manifesting as an 
array of symptoms and signs. Neuropathic pain can further be classified on the basis 
of etiology; thus, lesions can be central or peripheral, focal or generalized. There are 
multiple screening tools to aid in the diagnosis of neuropathic pain, including the 
Leeds Assessment of Neuropathic Symptoms and Signs (LANSS), Douleur 
Neuropathique 4 (DN4), Pain detect, ID Pain, and neuropathic pain questionnaire.
2, 3
 
A recent systematic review reported an estimated population prevalence 
of pain with neuropathic characteristics of between 6.9% and 10%.
4, 5
 
For South Africa, no published prevalence studies of neuropathic pain could be found. 
However, it is possible that there is a higher prevalence than elsewhere due to the 
burden of HIV/AIDS and diabetes, both of which are often associated with painful 
peripheral neuropathies. The prevalence of neuropathic pain was reported as 23% 
among South African AIDS patients who had not received prior antiretroviral 
treatment, increasing to 40% in HIV-positive black South Africans exposed to 
stavudine. 
7
 Stavudine, a nucleoside reverse transcriptase antiretroviral is neurotoxic, 
causing peripheral neuropathy in a dose dependent manner. The wide spectrum of 
diseases with a neuropathic component, combined with the different tools used to 
diagnose neuropathic pain, makes evaluation of epidemiological studies difficult.   
The pathology of neuropathic pain is complex and it is therefore not surprising that all 
treatment guidelines recommend multimodal treatment strategies and a 
biopsychosocial approach.
8
 To select the most effective multimodal approach, the 
pathological mechanisms that contribute to neuropathic pain need to be considered to 
inform the selection of treatments that target those mechanisms.  
The consequences of lesions in the somatosensory system include peripheral and 
central sensitization.
9
 Lesions in the peripheral nerves result in peripheral 
sensitization via an increased expression of Na
+
 channels and voltage gated Ca
2+
 
channels in the C- and Aδ-nociceptive fibres. This sensitization results in spontaneous 
ectopic-like discharges, decreased threshold of activation, and enhanced 
responsiveness to stimuli.
9
 Input from sensitized C-fibres can initiate and maintain 
activity dependant central sensitization in the dorsal horn of the spinal cord with 
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enhanced neural excitability due to enhanced neurotransmitter release (glutamate) and 
upregulation of glutamate (N-Methyl D-Aspartate) NMDA receptors.
10
 The enhanced 
excitability and upregulation results in expansion of the receptive field and abnormal 
neural sprouting within the dorsal horn of the spinal cord.
9, 10
 All these changes alter 
nociceptive transmission manifesting clinically as hyperalgesia and allodynia.  
Another mechanism that contributes to central sensitization is the dysfunction of the 
descending inhibitory serotonergic and noradrenergic pathways. Originating from the 
anterior cingulate gyrus, amygdala and hypothalamus, and traveling via the brain stem 
nuclei in the periaqueductal grey and rostroventral medial medulla, the descending 
inhibitory pathways modulate the spinal transmission of nociceptive input at the 
spinal cord.
10
 The neurotransmitters involved include noradrenaline, serotonin, and 
endogenous opioids. After a nerve injury, these pathways begin to dysfunction 
resulting in the effect of noradrenaline on α2 noradrenergic receptors being suspended, 
with a net effect of the serotonergic input changing from inhibition to facilitation. 
11
 
Therefore, the use of tricyclic antidepressants and serotonin noradrenaline reuptake 
inhibitors (SNRI) in the treatment of NP aims to facilitate endogenous inhibition and 
inhibit central sensitization. 
As is evident from the above discussion of neuropathic mechanisms, the Ca
2+ 
channels in the spinal cord are potential targets for the treatment of neuropathic pain. 
Ca
2+
 is required for exocytosis of vesicles containing neurotransmitters from the 
presynaptic neuron into the synapse. By blocking or decreasing activity of the Ca
2+ 
channels, a reduction in the synaptic release of excitatory neurotransmitters such as 
glutamate, substance P, noradrenaline, serotonin and calcitonin gene-related peptide 
results. By reducing the release of excitatory neurotransmitters, the effect of 
peripheral sensitization can be reduced, and central sensitization mechanisms 
diminished. The gabapentinoids, derivatives of the inhibitory neurotransmitter g-
aminobutyric acid (GABA), bind to the α2δ auxiliary subunit of voltage-gated calcium 
channels, decreasing the influx of Ca
2+
 into the presynaptic neuron.
12
   
The gabapentinoids include Pregabalin and gabapentin. Pregabalin is more potent and 
has a higher binding affinity for the α2δ subunit of voltage gated calcium channels 
than gabapentin.
12
 In South Africa, Pregabalin is currently recommended as a first line 
drug for treatment of neuropathic pain. The recommenations comes from an expert 
panel. 
13
 Pregabalin is hydrophilic and double stranded at neutral pH, and so it crosses 
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membrane barriers via a specialised transport system (system L). 
12, 31
 Pregabalin has 
an oral bioavailability of up to 90% and time to peak plasma concentration in healthy 
volunteers is one hour.  Absorption of Pregabalin is not saturable, resulting in a linear 
pharmacokinetic profile.  It undergoes less than 1% metabolism and 95% is excreted 
unchanged by the kidneys. As Pregabalin clearance decreases with increasing age and 
decreased creatine clearance, dose reduction is recommended in elderly patients (>65 
years) and patients with compromised renal function.  
Pregabalin has been used at the GSH Chronic Pain Clinic for eight years. The license 
on the drug has recently expired, and, with a potential shift in availability, it is 
appropriate to conduct a Medicines Usage Evaluation (MUE) to optimize future 
practice. GSH Chronic Pain Clinic is a specialist run clinic, treating an average of 100 
patients monthly. At GSH, in line with WC DoH guidelines, Pregabalin and 
gabapentin must be consultant initiated i.e. prescriptions cannot be filled without the 
approval of a consultant aneasthetist listed as working in the Chronic Pain Clinic. On 
average, patients seen at the clinic are 52.8 y; predominantly female (68.7%) and 
unemployed (51%), ( personal communication from Dr Van Vrede). We conducted a 
MUE of Pregabalin in the chronic pain management clinic (CPMC) of Groote Schuur 
Hospital to describe the prescription pattern and clinical use.  
  
METHODS 
A cross-sectional retrospective descriptive chart review of the use of Pregabalin in 
Groote Schuur chronic pain clinic for the year 2017 was conducted. This type of study 
design allows the researchers to investigate the characteristics of this specific 
population at one point in time and helps to identify the indications for Pregabalin 
prescription.  
To obtain a representative sample of prescribing practices in this population, the 
WHO recommends sampling a population of 100 patients. 
28
 As this study aimed to 
describe prescribing practice of clinicians in the Groote Schuur chronic pain 
management clinic, the population was patients being treated with Pregabalin at the 
CPMC of GSH in one year.  
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Ethical approval was obtained from the Faculty of Health Sciences Human Research 
Ethics Committee (Ref: 278/2018), Groote Schuur Hospital Department of Health 
(DoH) Ethics Committee and the Groote Schuur hospital pharmacy manager. 
 
Figure 1: Flow chart illustrating data collection process. 
 
From a list of 174 patients receiving Pregabalin in 2017, 100 folders were retrieved. 
(Figure 1). A medicine use evaluation (MUE) chart for Pregabalin based on the 
literature was developed (Appendix A). Each question in the data collection chart was 
peer reviewed by a chronic pain specialist. Items on the data collection sheet included: 
a documented diagnosis of neuropathic pain, the diagnostic tool used for the 
diagnosis, and documentation of the severity and duration of the condition. Charts 
were also examined to determine the presence of patient associated factors including 
age, gender, and presence of co-morbidities, allergies, pregnancy and breastfeeding. 
Data were collected on the prescribing practice of the clinician with respect to 
documentation of dosage, interval and duration of pregabalin, consideration of other 
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medications used by the patient and the possible interactions. Data from the MUE 
were entered into an excel spreadsheet. Descriptive statistics were used to summarize 
the data that are presented as mean (SD) or frequencies. 
 
RESULTS 
The mean patient age was 55.9y (SD12.49), ranging from 27y to 88y, and the 
majority (76 out of 100) were women (Table I). In all of the 100 folders reviewed, 
patient details including age, gender, presence of co-morbidities and allergies were 
documented. In one folder, note was made that screening for pregnancy was 
performed. In terms of socioeconomic profile, all 100 folders had documentation of 
whether the patient was receiving some form of social grant (disability grant or 
pension) with 36 documented as receiving a grant (Table I). 
 
Table I: Demographic characteristics (n=100) 
Descriptor Mean (SD) 
Age   
55.9 (12.49) 





Receiving a social grant 
36 
Applying for a disability grant 
6 
Temporary disability grant 
7 
Permanent disability grant 
22 
Workmen’s compensation application 
1 
 
Diagnosis of Neuropathic Pain 
The first criteria explored in the MUE was whether a diagnosis of NP was 
documented and whether a diagnostic tool was used to assist in making the diagnosis. 
A “diagnosis of NP” was classified as being made if the notes specified neuropathic 
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pain, neuropathy, radiculopathy, complex regional pain syndrome (CRPS) or post-
herpetic neuralgia. A “possible diagnosis of NP” was classified as being made if the 
terms “possible” or “query” were used in the documentation in conjunction with any 
of the above terms. If no documentation was found using the above terms, a diagnosis 
of NP was recorded as not being documented. A clear diagnosis of NP was 
documented in 58 of the folders with a “possible” diagnosis recorded in a further 
seven folders (Table II). 
 
Table II: Recording of Neuropathic pain diagnosis and method used (n=100) 
Diagnosis of Neuropathic Pain Recorded Frequency 
(%) 
Yes 58 
Possible diagnosis 7 
No 35 
  
Diagnostic tool/method recorded  
None recorded 79 
Yes (EMG method recorded) 2 
Yes (used a diagnostic tool) 19 
 
The DN4 was used as a diagnostic tool for NP in one of the folders reviewed. The 
Budapest Criteria for the diagnosis of CRPS were completed in 18 folders. The 
criteria confirmed the diagnosis of CRPS in 9 cases (four CRPS Type 1; five CRPS 
Type II), with nine cases not meeting the criteria for CRPS. In two folders, EMG 
studies were documented as being performed, one of these was normal and one 
confirmed a diagnosis of NP.  
The most common diagnoses were the neuropathic pain syndromes, which were 
recorded in 35 of the folders (Table III). The most common single condition 
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diagnosed was chronic post-surgical pain with a neuropathic component (n=16). This 
was followed by a diagnosis of neuropathic pain (n=15) and radiculopathy (n=12).  
 
Table III: Diagnoses recorded in the patient folders  
Diagnosis Frequency (%) 
Neuropathic diagnoses 35 
Neuropathic pain 15 
Complex regional pain syndrome Type 2 5 
Complex regional pain syndrome Type I 4 
Trigeminal neuralgia 3 
Post herpetic neuralgia 3 
Phantom limb pain 2 
Peripheral neuropathy 1 
Retroviral disease peripheral neuropathy 1 
Motor axonal neuropathy 1 
  
Spinal pain 26 
Radiculopathy 12 
Spinal stenosis 7 
Chronic lower back pain 4 
Tuberculosis of the spine 1 
Spondylosis 1 
Chronic lower back pain with neuropathic pain 1 
  
Chronic post-surgical pain 25 
Chronic post-surgical pain with a neuropathic component 16 
Failed back syndrome 5 
Chronic post-surgical pain 2 
Failed back syndrome with fibromyalgia 1 




Chronic pelvic pain 3 
Chronic epigastric pain 1 
Carpal tunnel syndrome & fibromyalgia 1 
Loin pain haematuria 1 
Chronic pancreatitis 1 
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Documentation of condition (pain severity, duration) 
Pain severity was documented in 96 of the folders reviewed. The Brief Pain Inventory 
32
 was used to record pain severity and pain interference with function in 87 of the 
folders. Other methods used to record pain severity were the verbal rating scale 
(mild/moderate/severe) (n=8), and the visual analogue scale (n=1). The length of time 
the symptoms had been present was documented in all 100 folders with either the date 
of injury or surgery recorded or the number of months/years since the onset of pain.   
 
Documentation of medical management 
In 99 of the folders, there was clear documentation regarding medication other than 
Pregabalin being prescribed. In 11 of these folders, potential interactions with 
Pregabalin were noted.  
In terms of Pregabalin dosages, clear prescribing was documented in all 100 folders 
including dosage, interval and duration. The most common initiating dose was 75mg 
twice daily (Table IV). There was a wide variety of current doses recorded with the 















Table IV: Frequency of initiating doses of Pregabalin (n=100) 
Initiating Dose Frequency 
(%) 
Night only  
25 mg  14 
50mg  2 
75mg  15 
Total night only 31 
Twice daily  







75mg  20 
100mg  1 
150mg  5 
300mg  3 













Table V: Frequency of current doses of Pregabalin (n=100) 
Current dose Frequency 
(%) 
Night only  
25mg  5 
50mg  4 
75mg  14 
150mg  1 
  
Twice daily  
Uneven dosing  
25mg morning/75mg night 9 
50mg morning/75mg night 2 
50mg morning/100mg night 1 
25mg morning/150mg night 1 
50mg morning150mg night 1 
75mg morning/150mg night 7 
100mg morning/150mg night 2 
75mg morning/225mg night 1 
150mg morning/225mg night 2 
150mg morning/300mg night 1 
150mg morning/300mg night 2 
275 mg morning/300mg night 1 
Even dosing  
25mg  1 
75mg  21 
150mg  17 
225mg  2 








Patients were receiving a wide variety of other medications indicated for pain 
including analgesics and centrally acting drugs (Table VI). The majority, (95 patients) 
were receiving analgesics in addition to pregabalin. Only five patients were receiving 
no medication other than pregabalin.  
There were 56 cases where Pregabalin was prescribed in conjunction with an 
antidepressant (TCA or SNRI). Notably, in seven folders, patients were prescribed 
Pregabalin with both a TCA and a SNRI.  More than half of the patients were on weak 
opioids, (tramadol, n=50) with a further 14 on morphine.   
 
A follow up plan in terms of a reassessment date to evaluate the effect of the 
treatment was documented in all 100 folders. In 96 of the folders, patients were 




Patient education was documented as having taken place in 76 of the folders. The 
education conducted varied in topic. In 28 folders it was recorded that patients were 
educated about pregabalin, its effects and potential side effects. In 30 folders it was 
recorded that patients received pain neuroscience education. In 48 folders it was 
recorded that patients were referred to the Physiotherapy led Chronic Pain 
Management Program which includes education on both pharmacological and non-
pharmacological management of pain, pain neuroscience education, self-management 
training, exercise and relaxation training. Seven of the 48 referred to this program 
were documented as not having attended.  
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Paracetamol  Amitriptyline (nocte) 37 Carbamazepine 7 Prednisone  
1g QID 78 10mg 7 100mg 4 7.5mg 1 
1g TDS 6 25mg 12 200mg 3 60mg 1 
  50mg 10     
Tramadol  75mg 5 Clonidine (25-150mcg) 8   
100mg QID 36 100mg 2     
50mg TDS 10 200mg 1 Baclofen    
100mg TDS 2   10mg TDS 1   
50mg BD 1 Venlafaxine 19 20mg TDS 1   
25mg 1 150mg 3     
  175mg 11     
Morphine  225mg 4     
10mg QID 6 300mg 1     
20mg QID 8       
  Mianserin 30mg 2     
  Fluoxetine 20mg 1     




A cross-sectional retrospective MUE of the use of Pregabalin at Groote Schuur Chronic Pain 
management Clinic in 2017 was conducted.  The mean age of the patients reviewed was 55.9 
years (SD12.49); a large proportion were females (n=76) and more than a quarter (n=36) 
were receiving or applying for social grants. Although it is possible that our population was 
biased, as Groote Schuur Hospital is an academic tertiary hospital that predominantly 
services those who do not have access to private health insurance or private healthcare, this 
profile is similar to that reported in the literature on chronic neuropathic pain with the 




Comparison of our patient population with medicines usage evaluations in countries as varied 
as the United Kingdom, Sweden and Japan shows a similar pattern with regard to age and 
gender distribution.  The UK cohort, had a median age of 59y and the majority were female 
(60.1%) 
33
, while in Sweden the median age was 55 years, of which 63% were female
34
. The 
Japanese cohort was slightly older (66.8y) with 51% females.
35
 
In this study, the most common condition diagnosed was chronic post-surgical pain with a 
neuropathic component (n=16). Post-traumatic and post-surgical nerve injuries are common 
causes of NP with post-herpetic neuralgia and distal polyneuropathy the next most common 
causes. 
36, 37
 In a tertiary care hospital in Saudi Arabia, the majority of patients were receiving 
Pregabalin for painful diabetic neuropathy
38
 whereas a UK primary care setting reported that 
only 17.8% of the Pregabalin prescriptions were for neuropathic pain with the majority being 
for epilepsy.
33
 The GSH cohort appeared to be different, with spinal related neuropathic pain 
being more common than the post-herpetic neuralgias and distal polyneuropathies reported as 
the most common conditions in other settings. This might be due to the presence of a 
specialist diabetic clinic at the hospital where patients with diabetic related distal 
polyneuropathy may be managed without referral to the pain clinic. Alternatively, these 
patients may be receiving treatment at a primary health care level. It is likely that these 
patients are being treated elsewhere as the incidence of both painful diabetic neuropathy and 
post herpetic neuralgia in South Africa are reported to be higher than elsewhere in the world 






According to the South African guidelines, Pregabalin is indicated for use in the presence of 
neuropathic pain only, specifically for post-herpetic neuralgia and painful diabetic 
neuropathy. 
13-15
 It is encouraging that in the majority of folders reviewed, Pregabalin was 
being prescribed according to evidence-based guidelines unlike the 35.5 % diagnostic rate of 
neuropathic pain reported in a Swedish setting.
34
 However, this diagnostic rate still falls short 
of expectations. 
The diagnosis of NP is made on history and clinical examination, which can be facilitated by 
a variety of screening tools. There are five validated screening tools recommended for use in 
the diagnosis of neuropathic pain: the DN4, LANSS, PainDETECT, ID pain and Neuropathic 
pain questionnaire.
3
 Most of these tools have a sensitivity and specificity of about 80% 
3
 
indicating that the screening tools fail to clearly identify neuropathic pain in 20% of cases. In 
an ideal practice setting, a MUE of Pregabalin where screening tools are routinely used 
would report 80% of the patients as having a clear diagnosis of neuropathic pain and the 
remainder being diagnosed with “possible” neuropathic pain. In this study, a neuropathic pain 
screening tool was only used in 21 cases. The routine use of neuropathic screening tools may 
optimize the diagnosis and management of neuropathic pain. 
Current guidelines recommend initiating Pregabalin at a dosage of 25mg at night to minimize 
initial side effects; with a maximum dose of 300-400mg daily in divided doses, to minimize 
dose dependent side effects. 
8, 13, 41
 The South African Medicines Formulary (SAMF),  
Monthly Index of Medical Specialities  (MIMS) and the Pregabalin package insert 
recommend different initiating doses from those in the guidelines.
14, 15
 In the SAMF and 
MIMS this is 75mg twice daily, while 150mg in two or three divided doses is specified in the 
package insert. This difference in recommendations, might contribute to variations in the 
prescribed initiating dose for pregabalin. Several factors have been identified which directly 
and indirectly affect prescribing patterns. 
42
 These include the clinical and behavioral 
characteristics of the patient, scientific evidence, drug efficacy, habitual or non-habitual 
choice, peer influence (community of physicians), education and  pharmaceutical advertising, 
and the high cost of drugs. The patients seen at chronic pain clinic are usually patients that 
have experienced incomplete or failed management from another hospital or specialist clinic, 
and so they often present with complex pathology and anxiety. Pregabalin’s high symptom 
amelioration and effectiveness makes it a common first line drug for the treatment of 
neuropathic pain. Peer influence may play a role as the clinic is staffed by one consultant 
with registrars rotating every two months. It is likely that the consultant influences the 
38 
 
registrar prescribing pattern more than the current literature as a consequence of the 
conflicting recommendations.
13, 14
 However, to make a definitive statement regarding the 
influence of these factors on prescriber practice, a study of clinical reasoning processes is 
needed.  
The efficacy of simple analgesics for neuropathic pain has not been established. However, 84 
patients were on paracetamol, a simple analgesic agent. As mentioned above, physician 
prescribing practice is influenced by multiple factors. The high usage of paracetamol might 
be due to the concomitant presence of complex pain with a nociceptive component (the 
clinical characteristics of the patient) or to prescribing practices related to habit and peer 
influence. 
42
 In addition, 56 patients were on combination treatment with an SNRI or TCA. 
These antidepressants are recommended for the management of neuropathic pain as first line 
(monotherapy) or second line (combination) therapy with pregabalin. 
8, 13, 41
 The concomitant 
use of these drugs in neuropathic pain target the mechanisms of dysfunction in the 
descending inhibitory pathway and address the mood and sleep disorders associated with 
chronic pain states. As mentioned in the introduction, the neurotransmitters involved in this 
pathway include serotonin and noradrenaline. The use of these drugs in addition to Pregabalin 
potentiates the descending inhibitory pathways and thus inhibits central sensitization.  
In all 100 folders reviewed, documentation of medical conditions, allergies, and medication 
doses were correctly recorded. In addition, pain severity was fully documented using the 
Brief Pain Inventory (BPI) in 96 of the folders reviewed. There was a 100% follow up of 
patients, where treatment effectiveness and development of side effects was reviewed. The 
excellent documentation and follow up is most likely achieved due to the use of a 
standardised assessment document used in the initial assessment of the patient. This 
standardised assessment document incorporates the BPI in addition to sections for past 
medical history (including history of mental health disorders), social history, level of 
education and employment, current mood and evaluation of the patient’s ideas, concerns and 
expectations. Therefore, this document thoroughly covers a biopsychosocial patient history 
and allows for the documentation of the management plan by the interdisciplinary team. The 
use of this document means every patient assessment is standardized, reminds clinicians of 
important factors to document, and reduces the risk of clinician bias or fatigue, habitual 
choices and peer influence, and facilitates patient follow up.
43
 
All current guidelines on the management of neuropathic pain and any chronic pain state 
emphasize the importance of a multidisciplinary team approach to the treatment of 
39 
 
neuropathic pain, as well as the role of patient education. 
13, 27, 37
 In this MUE, 96 patients 
were referred for non-pharmacological management of pain, documented as referral for 
physiotherapy, psychiatry, psychology, mirror therapy, graded motor imagery therapy, 
breathing and relaxation techniques. Patient education was specifically recorded in 76 of the 
folders; including education about pregabalin, its effects and side effects, pain neuroscience 
and the chronic pain management program. Documentation included decisions made at 
regular interdisciplinary meetings (medical doctors, physiotherapists, psychologists, 
consultation liaison psychiatrists) where each new patient is discussed, and appropriate 
management plans developed according to guidelines recommending holistic, 
pharmacological and non-pharmacological approaches for better efficacy. 
37
  
This study was a retrospective descriptive chart review of one hundred randomly selected 
folders reducing selection bias. Misclassification bias was minimized by the investigators 
performing all the data collection. The 100 folders represent 57.47% of the prescriptions 
written for Pregabalin by the chronic pain clinic in one year, limiting generalizability. Our 
study was conducted in an academic, public hospital where the patient population may be of 
lower socioeconomic status and have a higher burden of co-morbidities than elsewhere  
 
CONCLUSION 
Based on this study we recommend the routine use of screening tools in the diagnosis of 
neuropathic pain, in particular the use of the DN4 screening tool as per the South African 
guidelines.
13
 This recommendation was made because the DN4 is short, quick and easy to 
follow in regular clinical practice.We also recommend initiating Pregabalin at a dose of 25mg 
at night and titrating subsequent doses over one to two weeks based on efficacy and side 
effects to a maximum of 400mg daily in divided doses. Finally, we recommend that the risks 
of polypharmacy be raised with prescribers with emphasis on ceasing drugs that are not 
effective for the treatment of any given condition.  The use of Pregabalin in this Chronic Pain 
Management clinic is characterized by appropriate prescribing for neuropathic pain, good 
clinical documentation and appropriate management with follow up. This clinical practice 
may have been facilitated by the use of a standardized assessment document, the involvement 
of an interdisciplinary team with every new patient and active engagement with patients 
regarding treatment options. It would be beneficial to specifically explore the effects of these 
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Section D: Conclusion 
The use of Pregabalin in this Chronic Pain Management clinic appears to be characterized by 
appropriate prescribing for neuropathic pain, good clinical documentation and appropriate 
management with follow up. This clinical practice may have been facilitated by the use of a 
standardized assessment document, the involvement of an interdisciplinary team with every 
new patient and active engagement with patients regarding treatment options.  
 
Based on this MUE, we recommend the routine use of screening tools in the diagnosis of 
neuropathic pain, in particular the use of the DN4 screening tool as per the South African 
guidelines.
13
 We also recommend initiating Pregabalin at a dose of 25mg at night and 
titrating subsequent doses over one to two weeks based on efficacy and side effects to a 
maximum of 400mg daily in divided doses. Finally, we recommend that the risks of 
polypharmacy be raised with prescribers with emphasis on ceasing drugs that are not 
effective for the treatment of any given condition. 
 
This study was a retrospective descriptive chart review of one hundred randomly selected 
folders. This type of study is associated with recall and classification bias. To reduce  
selection bias, random selection of 100 folders was performed and misclassification bias was 
minimized by the investigators performing all the data collection. The 100 folders represent 
57.47% of the prescriptions written for Pregabalin by the chronic pain clinic in one year, 
limiting generalizability. Our study was conducted in an academic, public hospital where the 
patient population may be of lower socioeconomic status and have a higher burden of co-
morbidities than elsewhere. Another limitation of chart reviews is the reliance on 
documentation alone. There is a risk that patients may have been screened for pregnancy and 
negative responses were not documented with no room elaboration of what was discussed 
during patient education of pain and medication side effects in the notes. 
 
Future research needs to be focussed on the translation and validation of neuropathic pain 
screening tools for use in South African populations. This study provides a basis of 
comparison of Pregabalin use and neuropathic  pain treatment amongs clinician in private and 
state institutes. A detailed investigation of the prescribing practice of clinicians in  Groote 
Schuur Hospital chronic pain management clinic can assist in identify specific factors that 












Appendix B: Data Collection Documents ( Medicines usage evaluation) 






Has the clinician 
documented neuropathic 
pain as the diagnosis? 




Was a diagnostic tool such 
as the DN4/LANSS or 




Chetty, S., et al., 
2012 
SEVERITY Has the clinician 
documented severity of the 
pain? Either 
mild/moderate/severe or 












DURATION Has the duration of the pain 
































Finch, E., E.L. 


















Has the clinician mentioned 
and taken note of other 
medication the patient is on 










Has the dosage, interval and 
duration for which 










1. Has the clinician set a date 
for reassessment? During 
reassessment was the pain 
reassessed in terms of 
improved function and 
severity? 














Did the clinician mention a 
discussion with the patient in 
terms of possible side effects 






OF Y/N (x/11) 





 Appendix C: Standardized assessment dcument 
Groote Schuur Hospital  
PAIN MANAGEMENT CLINIC 
 
 
PATIENT STICKER:   
 
REFERRING DOCTOR:   
SPECIALITY: 
TODAY’S DATE:    
CLERKING DOCTOR:     
HISTORY OF PAIN:   
     
     
       
SITE:     
PRECIPITATING EVENT:   
DATE OF ONSET:    
RADIATION: 
    
EXACERBATING FACTORS:  
  
     
ANALGESICS (CURRENT):  
 
ANALGESICS (PREVIOUSLY):  
 
 
OTHER SPECIALITIES INVOLVED AND TREATMENTS GIVEN:  
     
 
 
    
MEDICAL HISTORY: 
 
CNS:    
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CVS:    
    
RESP:    
    
GIT:    
    
GUT:    
    
GYNAE:    
RENAL:    
ENDOCRINE:   
    
 




    
 
ALLERGIES:   
     
SOCIAL HISTORY: 
Occupation/Level of Education:   
 
Marital Status/Children:                
 
 
Social support/Disability Grant:      
 
Exercise/Physical Activity:  
Alcohol Abuse:                  
Smoking:   
Other Agent Abuse:               







Previous history of psychiatric disorders:  
 




Lost interest in things you usually enjoy?  
 
What has your mood been like?  
 
What are your expectations of this clinic? 
 
 
















































Abnormal Hair Growth: 
 






When doing a lower back pain evaluation think the following:  
Is this axial? (Muscular/ myofascial/ Facets) 
 
Or axial back pain with radiculopathy? (Referred leg pain)? 
 
Or previous surgery- failed back syndrome – which often has both features? 
BACK: 
General (appearance, palpation, mobility): 
MOVEMENTS: 
Flexion:     Extension:   Lateral (L):            Lateral: 
SLR(R):     SLR (L): 
POWER: 




















L3/L4 Patellar Reflex 










Flexion (degrees):    Extension:    Lateral (L)    Lateral (R)  
Rotation (L):    Rotation(R) 
Power:    Right  Left 
Shoulder abduction  
Elbow Flexion/Extension 
Wrist flexion/Extension 





Reflexes   Right   Left 
C5/C6 Biceps  
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TESTS AND INVESTIGATIONS 
Bloods: 




















Referral Team Members: 
Physiotherapy (1:1): 




Other Speciality:   









   
 
 
      
      




Appendix D: Reviewer comments and responses 
First Round of Review: 
COMMENTS RESPONSES 
Comment 1: Both reviewers feel that this 
title does not quite match the scope of 
your article. You have presented quite a 
detailed review of neuropathic pain and 
the role of the gabapentinoids in the 
management thereof.  
 
Thank you, we have tried to expand the 
title slightly to include the scope of the 
review and the MUE: 
“Gabapentinoids for treatment of 
neuropathic pain: a medicines usage 
evaluation at the Groote Schuur hospital 
chronic pain management clinic” 
Comment 2: 76 or 79? Differs in Table 1 
and the discussion 
Our apologies, the correct number is 76. 
This typing error has been corrected 
throughout. 
Comment 3: 76 female patients and 76 
cases with no mention of tool. This is 
unusual. Please confirm these figures 
 
79 cases with no mention of tool 
Typing error 
Comment 4: Please write out in full 
(predefine) before using abbreviations 
 
The full names have now been included: 
The Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS), Douleur 
Neuropathique 4 (DN4) 
Comment 5: “Soft reference (not a 
systematic review relevant to current 
practice as main deductions are from 
studies pre-dating NP diagnosis) #4 is not 
firm on prevalence and specifically 
mentions broad variations and challenges 
in diagnosis, specifically in Brazil. While 
of interest, this is not a NP article and 
broad statements and unqualified % 
unhelpful. “ Perhaps you could include a 
second reference here? 
 
Thank you for highlighting the need to 
provide more robust evidence. We have 
now included reference to a more recent 
systematic review of epidemiological 
studies 
“A recent systematic review reported an 
estimated population prevalence 
of pain with neuropathic characteristics 




Comment 6:  
Reviewer 1: Selection process is shown 
in the chart therefore this paragraph is 
unnecessary 
Reviewer 2: Were these new patients and 
new Pregabalin prescriptions in the 2017 
time frame specified? 
Editor: perhaps you can answer reviewer 
2 question and eliminate part of this 
paragraph, referring to the flow chart. 
 
We have streamlined the presentation of 
the procedure followed: 
“A total of 100 patient folders were 
reviewed; 35 prescriptions were made in 
2017 and 65 were from previous years. 
Figure 1” 
 
Comment 7:If 76 out of 100 were 
women, then this makes 76% unless you 
had some “non male non female” patients 
in the study, which should be indicated in 
the table 
 
Apologies and thanks for identifying this 
error. Corrected  
Comment 8 and 9:  76 or 79? Corrected throughout. Correct number 76 
Comment 10: I don’t think there is a 
reason to reiterate the results in the 
discussion section, only if the authors are 
drawing a comparison to other data or 
population. It is easier to say that such a 
% from our study shows this kind of NP 
and put this in perspective to published 
data. Ie is there any data on how 
Pregabalin is being prescribed in other 
pain units either in SA, or worldwide? 




We have reduced the repetition of results 
and drawn a comparison to other 
literature: 
“Comparison of our patient population 
with medicines usage evaluations in 
countries as varied as the United 
Kingdom, Sweden and Japan shows a 
similar pattern with regard to age and 
gender distribution.  The UK cohort, had 
a median age of 59y and the majority 
were female (60.1%) 
33
, while in Sweden 
the median age was 55 years, of which 
63% were female
34
. While the Japanese 
cohort was slightly older (66.8y) with 
51% females.”  
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“In a tertiary care hospital in Saudi 
Arabia, the majority of patients were 
receiving Pregabalin for painful diabetic 
neuropathy
38
 whereas a UK primary care 
setting reported that only 17,8% of the 
Pregabalin prescriptions were for 
neuropathic pain with the majority being 
for epilepsy. “ 
“It is encouraging that in the majority of 
folders reviewed, Pregabalin was being 
prescribed according to evidence-based 
guidelines unlike the 35.5 % diagnostic 
rate of neuropathic pain reported in a 
Swedish setting.”  
Comment 11:I do not understand this 
term. Do you mean a high curative effect 
or rate of cure? 
Thank you for highlighting the need to 
clarify the term – we have corrected 
throughout to “Curative effect”  
Comment 12: Curative effect See above 
Comment 13: Curative effect  
 
See above 
Comment 14: Many other effects on 
pain, peripheral nerves, NP, mood and 
sleep. 
 
We have included the following to 
clarify: “The concomitant use of these 
drugs in neuropathic pain target the 
mechanisms of dysfunction in the 
descending inhibitory pathway and 
address the mood and sleep disorders 
associated with chronic pain states..” 
 




We have rephrased the statement to 
clarify the scope of the Brief Pain 
Inventory and the scope of the entire pain 
assessment form used in the clinic: “This 
59 
 
standardised assessment document 
incorporates the BPI in addition to 
sections for past medical history 
(including history of mental health 
disorders), social history, level of 
education and employment, current mood 
and evaluation of the patient’s ideas, 
concerns and expectations.” 
 Comment 16: Each patient discussed? 
100 per month? 
 
We realise the way this was presented 
was ambiguous, we have clarified as 
follows: “Each new patient is discussed” 
Comment 17: I believe this discussion is 
lacking a reference to published data, rate 
of use of Pregabalin in the Middle East 
(might be a comparable population and 
closer demographics), and perhaps an 
international reference study. Other pain 
centres (stand alone, or part of tertiary 
hospitals) have their own long term 
records and the authors must show such a 
comparison.” I agree that a comparison 
with other pain units would strengthen 
this discussion 
 
Thank you for highlighting the need to 
provide more comparison data with 
similar populations and international 
studies: We have now included 
comparison from different countries in 
the discussion 
 
Comment 18: How often titrated? 
 
Details have been included: “We also 
recommend initiating Pregabalin at a 
dose of 25mg at night and titrating 
subsequent doses over one to two weeks 
based on efficacy and side effects to a 
maximum of 400mg daily in divided 
doses” 
Comment 19:Should some prescriptions 
not be ceased if ineffective as per NNT in 
We have clarified the language in this 
sentence by replacing the word 
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NP for Pregabalinand to avoid misuse? 
 
“removing” with “ceasing” 
Comment 20: How did you involve each 
patient. Do you mean “patient 
engagement” 
 
The concluding sentences have been 
adjusted as per the next comment. Please 
see below. 
 
Comment 21: Myself and reviewer 2 
think that this statement is quite 
presumptive based on the data presented 
in this MUE. The MUE was not intended 
to assess the efficacy of a standardized 
assessment document. Consider rewriting 
please. 
 
Indeed, the objective of this study was 
not to evaluate the assessment approach. 
We have adjusted the conclusion as 
follows: 
“The use of Pregabalin in this Chronic 
Pain Management clinic is characterized 
by appropriate prescribing for 
neuropathic pain, good clinical 
documentation and appropriate follow up. 
This clinical practice may have been 
facilitated by the use of a standardized 
assessment document, the involvement of 
an interdisciplinary team with every new 
patient and active engagement with 
patients regarding treatment options. It 
would be beneficial to specifically 






Second Round of Review: 
COMMENTS RESPONSE 
Comment 1: Formatting of flow chart 
needs attention as writing is partially 
obscured in the last box 
 
Thank you for highlighting the need to 
edit the table format. 
 
Comment 2: Is this correct? In Australia, 
Pregabalin is indicated for epilepsy and 
fibromyalgia. Not sure what it is 
registered for in SA. Please check this. 
 
Clarity has been provided as follows: 
According to the South African 
guidelines, Pregabalin  is indicated for 
use in the presence of neuropathic pain 
only, specifically for post-herpetic 
neuralgia and painful diabetic 
neuropathy. 
 
Comment 3: It may be worthwhile 
adding a comment that use of a valid 
diagnostic tool was only recorded in 21 
cases in your cohort, which is a low 
number. One might assume that all the 
other cases were diagnosed based on 
history and physical examination only? 
This would also reinforce your 
conclusion where you have recommended 
the use and documentation of DN4 
 
Thank you for highlighting the need to 
support the discussion:  In this study, a 
neuropathic pain screening tool was only 
used in 21 cases. The routine use of 
neuropathic screening tools may optimize 
the diagnosis and management of 
neuropathic pain.  
Comment 4: I read the reference article 
for this term and did not see the term 
used directly. I think you should change 
this to “drug efficacy” or “potential 
curative effect” 
Thank you for highlighting the need to 
clarify the term: Drug efficacy 
Comment 5: This sentence is redundant, 
as you have detailed the factors above – 




what you are trying to say 
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